Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology (original) (raw)

• Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
  PubMed Google Scholar
• Vogel, A., Meyer, T., Sapisochin, G., Salem, R. & Saborowski, A. Hepatocellular carcinoma. Lancet https://doi.org/10.1016/S0140-6736(22)01200-4 (2022).
  Article PubMed Google Scholar
• Rumgay, H. et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 77, 1598–1606 (2022).
  PubMed PubMed Central Google Scholar
• Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021).
  PubMed Google Scholar
• Moon, A. M., Singal, A. G. & Tapper, E. B. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin. Gastroenterol. Hepatol. 18, 2650–2666 (2020).
  PubMed Google Scholar
• Reveron-Thornton, R. F. et al. Global and regional long-term survival following resection for HCC in the recent decade: a meta-analysis of 110 studies. Hepatol. Commun. 6, 1813–1826 (2022).
  PubMed PubMed Central Google Scholar
• Koh, J. H. et al. Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients. Hepatobiliary Surg. Nutr. 11, 78–93 (2022).
  PubMed PubMed Central Google Scholar
• Sangro, B., Sarobe, P., Hervás-Stubbs, S. & Melero, I. Advances in immunotherapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 525–543 (2021).
  PubMed PubMed Central Google Scholar
• Vogel, A. & Martinelli, E. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines. Ann. Oncol. 32, 801–805 (2021).
  CAS PubMed Google Scholar
• Heimbach, J. K. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67, 358–380 (2018).
  PubMed Google Scholar
• EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J. Hepatol. 69, 182–236 (2018).
  Google Scholar
• Cheng, A.-L. et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76, 862–873 (2022).
  CAS PubMed Google Scholar
• Huang, D. Q. et al. Characteristics and outcomes of hepatocellular carcinoma patients with macrovascular invasion following surgical resection: a meta-analysis of 40 studies and 8,218 patients. Hepatobiliary Surg. Nutr. 11, 848–860 (2022).
  PubMed PubMed Central Google Scholar
• Tapper, E. B. & Parikh, N. D. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. Br. Med. J. 362, k2817 (2018).
  Google Scholar
• Huang, D. Q. et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 34, 969–977.e2 (2022).
  CAS PubMed PubMed Central Google Scholar
• El-Serag, H. B. & Rudolph, K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557–2576 (2007).
  CAS PubMed Google Scholar
• Omata, M. et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol. Int. 11, 317–370 (2017).
  PubMed Google Scholar
• Zhang, B.-H., Yang, B.-H. & Tang, Z.-Y. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 130, 417–422 (2004).
  PubMed Google Scholar
• Jepsen, P. & West, J. We need stronger evidence for (or against) hepatocellular carcinoma surveillance. J. Hepatol. 74, 1234–1239 (2021).
  PubMed Google Scholar
• Singal, A. G. et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J. Hepatol. 77, 128–139 (2022).
  PubMed PubMed Central Google Scholar
• Wolf, E., Rich, N. E., Marrero, J. A., Parikh, N. D. & Singal, A. G. Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis. Hepatology 73, 713–725 (2021).
  PubMed Google Scholar
• Nguyen, M. H. et al. Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States. Hepatol. Commun. 6, 3443–3456 (2022).
  CAS PubMed PubMed Central Google Scholar
• Ye, Q. et al. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. J. Hepatol. 76, 63–74 (2022).
  CAS PubMed Google Scholar
• Zhao, C. & Nguyen, M. H. Hepatocellular carcinoma screening and surveillance: practice guidelines and real-life practice. J. Clin. Gastroenterol. 50, 120–133 (2016).
  CAS PubMed Google Scholar
• Huang, D. Q., Mathurin, P., Cortez-Pinto, H. & Loomba, R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat. Rev. Gastroenterol. Hepatol. 20, 37–49 (2023).
  PubMed Google Scholar
• Tan, D. J. H. et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 23, 521–530 (2022).
  PubMed PubMed Central Google Scholar
• Simmons, O. et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment. Pharmacol. Ther. 45, 169–177 (2017).
  CAS PubMed Google Scholar
• Marrero, J. A. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68, 723–750 (2018).
  PubMed Google Scholar
• Singal, A. G. et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology https://doi.org/10.1097/hep.0000000000000466 (2023).
  Article PubMed Google Scholar
• Kim, J. H. et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J. Hepatol. 69, 1066–1073 (2018).
  PubMed Google Scholar
• Kanwal, F. & Singal, A. G. Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology 157, 54–64 (2019).
  PubMed Google Scholar
• Davila, J. A. et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann. Intern. Med. 154, 85–93 (2011).
  PubMed Google Scholar
• Goldberg, D. S. et al. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology 65, 864–874 (2017).
  PubMed Google Scholar
• Tran, S. A. et al. Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis. BMJ Open Gastroenterol. 5, e000192 (2018).
  PubMed PubMed Central Google Scholar
• Nguyen, M. H. et al. Gaps in hepatocellular carcinoma surveillance in a United States cohort of insured patients with cirrhosis. Curr. Med. Res. Opin. 38, 2163–2173 (2022).
  PubMed Google Scholar
• Yeo, Y. H. et al. Surveillance of patients with cirrhosis remains suboptimal in the United States. J. Hepatol. 75, 856–864 (2021).
  PubMed Google Scholar
• Zhao, C. et al. Poor adherence to hepatocellular carcinoma surveillance: a systematic review and meta-analysis of a complex issue. Liver Int. 38, 503–514 (2018).
  PubMed Google Scholar
• Wang, C. et al. Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B. Medicine 95, e4744 (2016).
  PubMed PubMed Central Google Scholar
• Singal, A. G. et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev. Res. 5, 1124–1130 (2012).
  Google Scholar
• Zhang, W. et al. Awareness and knowledge of nonalcoholic fatty liver disease among office employees in Beijing, Cchina. Dig. Dis. Sci. 64, 708–717 (2019).
  PubMed Google Scholar
• Jun, D. W. et al. A study of the awareness of chronic liver diseases among Korean adults. Korean J. Hepatol. 17, 99–105 (2011).
  PubMed PubMed Central Google Scholar
• Farvardin, S. et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology 65, 875–884 (2017).
  PubMed Google Scholar
• Singal, A. G. et al. Patient-reported barriers are associated with receipt of hepatocellular carcinoma surveillance in a multicenter cohort of patients with cirrhosis. Clin. Gastroenterol. Hepatol. 19, 987–995.e1 (2021).
  PubMed Google Scholar
• Rodriguez Villalvazo, Y. et al. Effect of travel distance and rurality of residence on initial surveillance for hepatocellular carcinoma in VA primary care patient with cirrhosis. Health Serv. Res. 55, 103–112 (2020).
  PubMed Google Scholar
• Teerasarntipan, T. et al. Physician- and patient-reported barriers to hepatocellular carcinoma surveillance: a nationwide survey. Medicine 101, e30538 (2022).
  PubMed Google Scholar
• Karlsen, T. H. et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399, 61–116 (2022).
  PubMed Google Scholar
• Walker, M. et al. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment. Pharmacol. Ther. 43, 621–630 (2016).
  CAS PubMed PubMed Central Google Scholar
• Alexander, M. et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med. 16, 130 (2018).
  PubMed PubMed Central Google Scholar
• Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851–861 (2022).
  PubMed Google Scholar
• Le, M. H. et al. 2019 Global NAFLD prevalence — a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 20, 2809–2817.e28 (2021).
  PubMed Google Scholar
• Simmons, O. L., Feng, Y., Parikh, N. D. & Singal, A. G. Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance. Clin. Gastroenterol. Hepatol. 17, 766–773 (2019).
  PubMed Google Scholar
• Tzartzeva, K. et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 154, 1706–1718.e1 (2018).
  CAS PubMed Google Scholar
• Tan, D. J. H. et al. UNOS down-staging criteria for liver transplantation of hepatocellular carcinoma: systematic review and meta-analysis of 25 studies. Clin. Gastroenterol. Hepatol. 21, 1475–1484 (2022).
  PubMed Google Scholar
• Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J. Hepatol. 76, 681–693 (2022).
  PubMed Google Scholar
• Del Poggio, P. et al. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 12, 1927–1933.e2 (2014).
  PubMed Google Scholar
• Fetzer, D. T. et al. Screening and surveillance of hepatocellular carcinoma: an introduction to ultrasound liver imaging reporting and data system. Radiol. Clin. North Am. 55, 1197–1209 (2017).
  PubMed Google Scholar
• Tang, A. et al. Introduction to the liver imaging reporting and data system for hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 17, 1228–1238 (2019).
  PubMed Google Scholar
• Schoenberger, H. et al. Dynamic changes in ultrasound quality for hepatocellular carcinoma screening in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 20, 1561–1569 (2021).
  PubMed PubMed Central Google Scholar
• Chong, N. et al. Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study. Aliment. Pharmacol. Ther. 55, 683–690 (2022).
  PubMed Google Scholar
• Atiq, O. et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology 65, 1196–1205 (2017).
  CAS PubMed Google Scholar
• Singal, A. G. et al. Benefits and harms of hepatocellular carcinoma surveillance in a prospective cohort of patients with cirrhosis. Clin. Gastroenterol. Hepatol. 19, 1925–1932.e1 (2021).
  PubMed Google Scholar
• Dale, W., Bilir, P., Han, M. & Meltzer, D. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer 104, 467–478 (2005).
  PubMed Google Scholar
• Tan, D. J. H. et al. Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH. Hepatology 77, 1150–1163 (2022).
  PubMed Google Scholar
• Ng, C. H., Huang, D. Q. & Nguyen, M. H. NAFLD versus MAFLD: prevalence, outcomes and implications of a change in name. Clin. Mol. Hepatol. 28, 790–801 (2022).
  PubMed PubMed Central Google Scholar
• Ng, C. H. et al. Examining the interim proposal for name change to steatotic liver disease in the US population. Hepatology 77, 1712–1721 (2023).
  PubMed Google Scholar
• Eslam, M. et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158, 1999–2014.e1 (2020).
  CAS PubMed Google Scholar
• Huang, D. Q. et al. Hepatocellular carcinoma incidence in alcohol-associated cirrhosis: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 21, 1169–1177 (2022).
  PubMed Google Scholar
• Orci, L. A. et al. Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Clin. Gastroenterol. Hepatol. 20, 283–292.e10 (2022).
  PubMed Google Scholar
• Kanwal, F. et al. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology 77, 997–1005 (2022).
  Google Scholar
• Ioannou, G. N., Green, P., Kerr, K. F. & Berry, K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J. Hepatol. 71, 523–533 (2019).
  PubMed PubMed Central Google Scholar
• Younossi, Z. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335–1347 (2019).
  Google Scholar
• World Health Organization. Global Status Report on Alcohol and Health 2018 https://www.who.int/publications/i/item/9789241565639 (2018).
• Huang, D. Q., El-Serag, H. B. & Loomba, R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 18, 223–238 (2021).
  PubMed Google Scholar
• Vitale, A. et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 72, 141–152 (2023).
  PubMed Google Scholar
• Karim, M. A. et al. Clinical characteristics and outcomes of nonalcoholic fatty liver disease-associated hepatocellular carcinoma in the United States. Clin. Gastroenterol. Hepatol. 21, 670–680.e18 (2022).
  PubMed Google Scholar
• Natarajan, Y. et al. Risk of cirrhosis and hepatocellular cancer in patients with NAFLD and normal liver enzymes. Hepatology 72, 1242–1252 (2020).
  CAS PubMed Google Scholar
• Kanwal, F. et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 155, 1828–1837.e2 (2018).
  PubMed Google Scholar
• Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 385, 1559–1569 (2021).
  CAS PubMed PubMed Central Google Scholar
• Simon, T. G. et al. Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study. Hepatology 74, 2410–2423 (2021).
  CAS PubMed Google Scholar
• Cucchetti, A., Cescon, M., Erroi, V. & Pinna, A. D. Cost-effectiveness of liver cancer screening. Best Pract. Res. Clin. Gastroenterol. 27, 961–972 (2013).
  PubMed Google Scholar
• Loomba, R., Lim, J. K., Patton, H. & El-Serag, H. B. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology 158, 1822–1830 (2020).
  PubMed Google Scholar
• Mózes, F. E. et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 71, 1006–1019 (2022).
  PubMed Google Scholar
• Loomba, R. & Adams, L. A. Advances in non-invasive assessment of hepatic fibrosis. Gut 69, 1343–1352 (2020).
  CAS PubMed Google Scholar
• Vali, Y. et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J. Hepatol. 73, 252–262 (2020).
  PubMed Google Scholar
• Loomba, R. et al. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut 72, 581–589 (2023).
  CAS PubMed Google Scholar
• Teng, M. L., Tan, D. J. H., Ng, C. H. & Huang, D. Q. Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease — who and how? Clin. Mol. Hepatol. 29, 404–407 (2023).
  PubMed PubMed Central Google Scholar
• Huang, D. Q. et al. Type 2 diabetes, hepatic decompensation and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis. Lancet Gastroenterol. Hepatol. https://doi.org/10.1016/S2468-1253(23)00157-7 (2023).
• Huang, D. Q., Wilson, L. A. & Behling, C. Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study. Gastroenterology https://doi.org/10.1053/j.gastro.2023.04.025 (2023).
  Article PubMed PubMed Central Google Scholar
• Kramer, J. R. et al. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology 75, 1420–1428 (2022).
  CAS PubMed Google Scholar
• Kanwal, F. et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology 71, 808–819 (2020).
  PubMed Google Scholar
• Cholankeril, G. et al. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J. Hepatol. 78, 493–500 (2023).
  CAS PubMed Google Scholar
• Ioannou, G. N. Epidemiology and risk-stratification of NAFLD-associated HCC. J. Hepatol. 75, 1476–1484 (2021).
  PubMed Google Scholar
• Nemutlu, G., Hajjar, A. & Mueller, P. Which individuals with nonalcoholic fatty liver disease should undergo HCC surveillance? cost-effectiveness analysis. Hepatology 76, S1–S1564 (2022).
  Google Scholar
• Quek, J. et al. Quality assessment of ultrasound and magnetic resonance imaging for hepatocellular carcinoma surveillance: systematic review and meta-analysis. Dig. Dis. https://doi.org/10.1159/000531016 (2023).
  Article PubMed Google Scholar
• Huang, D. Q. et al. Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: a prospective study. Aliment. Pharmacol. Ther. 55, 820–827 (2022).
  CAS PubMed PubMed Central Google Scholar
• McNeely, J. et al. Barriers and facilitators affecting the implementation of substance use screening in primary care clinics: a qualitative study of patients, providers, and staff. Addict. Sci. Clin. Pract. 13, 8 (2018).
  PubMed PubMed Central Google Scholar
• DiMartini, A. F., Leggio, L. & Singal, A. K. Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models. Lancet Gastroenterol. Hepatol. 7, 186–195 (2022).
  PubMed Google Scholar
• Bucci, L. et al. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Aliment. Pharmacol. Ther. 43, 385–399 (2016).
  CAS PubMed Google Scholar
• Schutte, K. et al. Delayed diagnosis of HCC with chronic alcoholic liver disease. Liver Cancer 1, 257–266 (2012).
  PubMed PubMed Central Google Scholar
• Costentin, C. E. et al. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective, nationwide study. Cancer 124, 1964–1972 (2018).
  PubMed Google Scholar
• Costentin, C. E. et al. Geographical disparities of outcomes of hepatocellular carcinoma in France: the heavier burden of alcohol compared to hepatitis C. Dig. Dis. Sci. 65, 301–311 (2020).
  CAS PubMed Google Scholar
• Seitz, H. K. et al. Alcoholic liver disease. Nat. Rev. Dis. Prim. 4, 16 (2018).
  PubMed Google Scholar
• Keyes, K. M. et al. Stigma and treatment for alcohol disorders in the United States. Am. J. Epidemiol. 172, 1364–1372 (2010).
  CAS PubMed PubMed Central Google Scholar
• Im, G. Y. et al. Provider attitudes and practices for alcohol screening, treatment, and education in patients with liver disease: a survey from the American Association for the Study of Liver Diseases Alcohol-associated Liver Disease Special Interest Group. Clin. Gastroenterol. Hepatol. 19, 2407–2416.e8 (2021).
  PubMed Google Scholar
• Bataller, R., Arab, J. P. & Shah, V. H. Alcohol-associated hepatitis. N. Engl. J. Med. 387, 2436–2448 (2022).
  CAS PubMed Google Scholar
• Jepsen, P. et al. Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis. J. Hepatol. 73, 1030–1036 (2020).
  PubMed Google Scholar
• Parikh, N. D., Singal, A. G., Hutton, D. W. & Tapper, E. B. Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms. Am. J. Gastroenterol. 115, 1642–1649 (2020).
  PubMed PubMed Central Google Scholar
• Singal, A. K. & Mathurin, P. Diagnosis and treatment of alcohol-associated liver disease: a review. J. Am. Med. Assoc. 326, 165–176 (2021).
  CAS Google Scholar
• Kim, N. J., Vutien, P., Cleveland, E., Cravero, A. & Ioannou, G. N. Fibrosis stage-specific incidence of hepatocellular cancer after hepatitis c cure with direct-acting antivirals: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 21, 1723–1738.e5 (2022).
  PubMed Google Scholar
• Kanwal, F. et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 153, 996–1005.e1 (2017).
  CAS PubMed Google Scholar
• Ioannou, G. N., Green, P. K. & Berry, K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J. Hepatol. https://doi.org/10.1016/j.jhep.2017.08.030 (2017).
  Article PubMed PubMed Central Google Scholar
• Calvaruso, V. et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 155, 411–421.e4 (2018).
  CAS PubMed Google Scholar
• Romano, A. et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J. Hepatol. 69, 345–352 (2018).
  CAS PubMed Google Scholar
• Ogawa, E. et al. Association of direct-acting antiviral therapy with liver and nonliver complications and long-term mortality in patients with chronic hepatitis C. JAMA Intern. Med. 183, 97–105 (2022).
  Google Scholar
• Dang, H. et al. Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both east and west. Hepatology 71, 1910–1922 (2020).
  CAS PubMed Google Scholar
• Shiha, G. et al. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: a prospective study. J. Viral Hepat. 27, 671–679 (2020).
  CAS PubMed Google Scholar
• Tanaka, Y. et al. HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. Hepatol. Int. 14, 1023–1033 (2020).
  PubMed Google Scholar
• Semmler, G. et al. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J. Hepatol. 76, 812–821 (2022).
  CAS PubMed Google Scholar
• DʼAmbrosio, R. et al. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J. Hepatol. 76, 302–310 (2022).
  PubMed Google Scholar
• Degasperi, E. et al. Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. Clin. Gastroenterol. Hepatol. 17, 1183–1191.e7 (2019).
  CAS PubMed Google Scholar
• Farhang Zangneh, H. et al. Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis c virus infection and advanced fibrosis. Clin. Gastroenterol. Hepatol. 17, 1840–1849.e16 (2019).
  PubMed Google Scholar
• Kanda, T. et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol. Int. 13, 649–661 (2019).
  PubMed Google Scholar
• Ioannou, G. N. et al. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J. Hepatol. 69, 1088–1098 (2018).
  PubMed PubMed Central Google Scholar
• Ioannou, G. N. HCC surveillance after SVR in patients with F3/F4 fibrosis. J. Hepatol. 74, 458–465 (2021).
  PubMed Google Scholar
• Le, M. H. et al. Chronic hepatitis B prevalence among foreign-born and U.S.-born adults in the United States, 1999-2016. Hepatology 71, 431–443 (2020).
  CAS PubMed Google Scholar
• Nguyen, M. H., Wong, G., Gane, E., Kao, J. H. & Dusheiko, G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin. Microbiol. Rev. 33, e00046–19 (2020).
  PubMed PubMed Central Google Scholar
• Tan, D. J. H. et al. Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis. JAMA Netw. Open 5, e2219407 (2022).
  PubMed PubMed Central Google Scholar
• Chan, A. C. Y. et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch. Surg. 146, 675–681 (2011).
  PubMed Google Scholar
• Hsu, Y. C., Huang, D. Q. & Nguyen, M. H. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat. Rev. Gastroenterol. Hepatol. https://doi.org/10.1038/s41575-023-00760-9 (2023).
  Article PubMed Google Scholar
• GBD 2019 Hepatitis B Collaborators.Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol. Hepatol. 7, 796–829 (2022).
  Google Scholar
• Yang, H. I. et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 12, 568–574 (2011).
  PubMed Google Scholar
• Lee, H. W. et al. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am. J. Gastroenterol. 109, 1241–1249 (2014).
  CAS PubMed Google Scholar
• Wong, V. W. et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J. Clin. Oncol. 28, 1660–1665 (2010).
  CAS PubMed Google Scholar
• Wong, G. L. et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J. Hepatol. 60, 339–345 (2014).
  PubMed Google Scholar
• Yuen, M. F. et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J. Hepatol. 50, 80–88 (2009).
  PubMed Google Scholar
• Yang, H. I. et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J. Clin. Oncol. 28, 2437–2444 (2010).
  PubMed Google Scholar
• Papatheodoridis, G. et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J. Hepatol. 64, 800–806 (2016).
  CAS PubMed Google Scholar
• Papatheodoridis, G. V. et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. J. Hepatol. 72, 1088–1096 (2020).
  CAS PubMed Google Scholar
• Voulgaris, T., Papatheodoridi, M., Lampertico, P. & Papatheodoridis, G. V. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. Liver Int. 40, 484–495 (2020).
  PubMed Google Scholar
• Yang, H. I. et al. REAL-B (Real-world effectiveness from the asia pacific rim liver consortium for HBV) risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy. J. Infect. Dis. 221, 389–399 (2019).
  Google Scholar
• Poh, Z. et al. Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. Gut 65, 887–888 (2016).
  CAS PubMed Google Scholar
• Papatheodoridis, G. V. et al. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. JHEP Rep. 3, 100290 (2021).
  PubMed PubMed Central Google Scholar
• Chen, C. J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J. Am. Med. Assoc. 295, 65–73 (2006).
  CAS Google Scholar
• Yu, J. H., Cho, S. G., Jin, Y.-J. & Lee, J.-W. The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection. Clin. Mol. Hepatol. 28, 351–361 (2022).
  PubMed Google Scholar
• Huang, D. Q. et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase. Clin. Gastroenterol. Hepatol. 20, 1803–1812.e5 (2022).
  CAS PubMed Google Scholar
• Chang, M.-L. & Liaw, Y.-F. Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management. J. Hepatol. 61, 1407–1417 (2014).
  PubMed Google Scholar
• Kim, H. S. et al. Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. J. Hepatol. 76, 294–301 (2022).
  CAS PubMed Google Scholar
• Yu, J. H. et al. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir. Eur. J. Gastroenterol. Hepatol. 31, 865–872 (2019).
  CAS PubMed Google Scholar
• Riveiro-Barciela, M. et al. Effectiveness and safety of entecavir or tenofovir in a spanish cohort of chronic hepatitis B patients: validation of the page-B score to predict hepatocellular carcinoma. Dig. Dis. Sci. 62, 784–793 (2017).
  CAS PubMed Google Scholar
• Kennedy, N. A. et al. Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study. Intern. Med. J. 43, 772–777 (2013).
  CAS PubMed Google Scholar
• Singal, A. G. et al. Multicenter randomized clinical trial of a mailed outreach strategy for hepatocellular carcinoma surveillance. Clin. Gastroenterol. Hepatol. 20, 2818–2825.e1 (2021).
  PubMed Google Scholar
• Del Poggio, P. et al. A training program for primary care physicians improves the effectiveness of ultrasound surveillance of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 27, 1103–1108 (2015).
  PubMed Google Scholar
• Beste, L. A. et al. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin. Gastroenterol. Hepatol. 13, 172–179 (2015).
  PubMed Google Scholar
• Aberra, F. B., Essenmacher, M., Fisher, N. & Volk, M. L. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig. Dis. Sci. 58, 1157–1160 (2013).
  PubMed Google Scholar
• Labenz, C. et al. Structured early detection of asymptomatic liver cirrhosis: results of the population-based liver screening program SEAL. J. Hepatol. 77, 695–701 (2022).
  PubMed Google Scholar
• Kudo, M. Japan’s successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance. Liver Cancer 1, 141–143 (2012).
  CAS PubMed PubMed Central Google Scholar
• Liao, S.-H. et al. Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan. J. Hepatol. 75, 132–141 (2021).
  PubMed Google Scholar
• Kudo, M. et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer 10, 181–223 (2021).
  CAS PubMed PubMed Central Google Scholar
• Toyoda, H. et al. Outcome of hepatocellular carcinoma detected during surveillance: comparing USA and Japan. Clin. Gastroenterol. Hepatol. 19, 2379–2388.e6 (2021).
  PubMed Google Scholar
• Johnson, P. et al. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. Br. J. Cancer 116, 441–447 (2017).
  PubMed PubMed Central Google Scholar
• Kuo, S.-C. et al. Optimal intervals of ultrasonography screening for early diagnosis of hepatocellular carcinoma in Taiwan. JAMA Netw. Open 4, e2114680 (2021).
  PubMed PubMed Central Google Scholar
• Alqahtani, S. A. et al. Poor awareness of liver disease among adults with NAFLD in the United States. Hepatol. Commun. 5, 1833–1847 (2021).
  PubMed PubMed Central Google Scholar
• Finberg, H. J. Whither (wither?) the ultrasound specialist? J. Ultrasound Med. 23, 1543–1547 (2004).
  PubMed Google Scholar
• Fetzer, D. T., Browning, T., Xi, Y., Yokoo, T. & Singal, A. G. Associations of ultrasound LI-RADS visualization score with examination, sonographer, and radiologist factors: retrospective assessment in over 10,000 examinations. AJR Am. J. Roentgenol. 218, 1010–1020 (2022).
  PubMed Google Scholar
• Parikh, N. D., Tayob, N. & Singal, A. G. Blood-based biomarkers for hepatocellular carcinoma screening: approaching the end of the ultrasound era? J. Hepatol. 78, 207–216 (2023).
  CAS PubMed Google Scholar
• Oka, H., Tamori, A., Kuroki, T., Kobayashi, K. & Yamamoto, S. Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 19, 61–66 (1994).
  CAS PubMed Google Scholar
• Lok, A. S. et al. Des-γ-carboxy prothrombin and α-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138, 493–502 (2010).
  CAS PubMed Google Scholar
• Marrero, J. A. et al. α-Fetoprotein, des-γ carboxyprothrombin, and lectin-bound α-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137, 110–118 (2009).
  CAS PubMed Google Scholar
• Singal, A. G. et al. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology 75, 541–549 (2022).
  CAS PubMed Google Scholar
• Kumada, T. et al. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J. Gastroenterol. 49, 555–563 (2014).
  CAS PubMed Google Scholar
• Tayob, N., Kanwal, F., Alsarraj, A., Hernaez, R. & El-Serag, H. B. The performance of AFP, AFP-3, DCP as biomarkers for detection of hepatocellular carcinoma (HCC): a phase 3 biomarker study in the United States. Clin. Gastroenterol. Hepatol. 21, 415–423 (2023).
  CAS PubMed Google Scholar
• Toyoda, H. et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin. Gastroenterol. Hepatol. 4, 1528–1536 (2006).
  CAS PubMed Google Scholar
• Fox, R. et al. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. Br. J. Cancer 110, 2090–2098 (2014).
  CAS PubMed PubMed Central Google Scholar
• Singal, A. G. et al. Doylestown plus and GALAD demonstrate high sensitivity for HCC detection in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 20, 953–955.e2 (2022).
  CAS PubMed Google Scholar
• Tayob, N. et al. Validation of the updated hepatocellular carcinoma early detection screening algorithm in a community-based cohort of patients with cirrhosis of multiple etiologies. Clin. Gastroenterol. Hepatol. 19, 1443–1450.e6 (2021).
  CAS PubMed Google Scholar
• Chalasani, N. P. et al. Validation of a novel multitarget blood test shows high sensitivity to detect early stage hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 20, 173–182.e7 (2022).
  CAS PubMed Google Scholar
• Lin, N. et al. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma. Hepatol. Commun. 6, 1753–1763 (2022).
  CAS PubMed PubMed Central Google Scholar
• Sun, N. et al. HCC EV ECG score: an extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma. Hepatology 77, 774–788 (2023).
  PubMed Google Scholar
• Singal, A. G. et al. International Liver Cancer Association (ILCA) white paper on biomarker development for hepatocellular carcinoma. Gastroenterology 160, 2572–2584 (2021).
  PubMed Google Scholar
• Johnson, P., Zhou, Q., Dao, D. Y. & Lo, Y. M. D. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 19, 670–681 (2022).
  PubMed Google Scholar
• Lee, Y. T., Fujiwara, N., Yang, J. D. & Hoshida, Y. Risk stratification and early detection biomarkers for precision HCC screening. Hepatology 78, 319–362 (2022).
  PubMed Google Scholar
• Kim, S. Y. et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol. 3, 456–463 (2017).
  PubMed PubMed Central Google Scholar
• Roberts, L. R. et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology 67, 401–421 (2018).
  PubMed Google Scholar
• An, J. Y. et al. Abbreviated MRI for hepatocellular carcinoma screening and surveillance. Radiographics 40, 1916–1931 (2020).
  PubMed Google Scholar
• Gupta, P. et al. Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. J. Hepatol. 75, 108–119 (2021).
  PubMed Google Scholar
• Park, H. J. et al. Abbreviated magnetic resonance imaging vs. ultrasound for surveillance of hepatocellular carcinoma in high-risk patients. Liver Int. 42, 2080–2092 (2021).
  PubMed Google Scholar
• Yokoo, T. et al. Multicenter validation of abbreviated MRI for detecting early-stage hepatocellular carcinoma. Radiology https://doi.org/10.1148/radiol.220917 (2023).
  Article PubMed Google Scholar
• GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol. Hepatol. 5, 245–266 (2020).
  Google Scholar
• World Health Organization. Global Hepatitis Report https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionid=6DB65DA61DB685B218A314037DBE0C09?sequence=1 (2017).
• Mohammed, H. A. et al. Factors influencing surveillance for hepatocellular carcinoma in patients with liver cirrhosis. Liver Cancer 6, 126–136 (2017).
  Google Scholar
• Signorelli, I. V. et al. Socioeconomic disparities in access to a hepatocellular carcinoma screening program in Brazil. Clinics 71, 361–364 (2016).
  PubMed PubMed Central Google Scholar
• Palmer, L. B., Kappelman, M. D., Sandler, R. S. & Hayashi, P. H. Surveillance for hepatocellular carcinoma in a Medicaid cirrhotic population. J. Clin. Gastroenterol. 47, 713–718 (2013).
  PubMed PubMed Central Google Scholar
• Singal, A. G., Tiro, J., Li, X., Adams-Huet, B. & Chubak, J. Hepatocellular carcinoma surveillance among patients with cirrhosis in a population-based integrated health care delivery system. J. Clin. Gastroenterol. 51, 650–655 (2017).
  CAS PubMed PubMed Central Google Scholar
• Chang, S. S. et al. Factors associated with nonadherence to surveillance for hepatocellular carcinoma among patients with hepatic C virus cirrhosis, 2000-2015. Medicine 101, e31907 (2022).
  PubMed PubMed Central Google Scholar
• Goldberg, D. S. et al. Hepatocellular carcinoma surveillance rates in commercially insured patients with noncirrhotic chronic hepatitis B. J. Viral Hepat. 22, 727–736 (2015).
  CAS PubMed PubMed Central Google Scholar
• Tran, S., Jeong, D., Henry, L., Cheung, R. C. & Nguyen, M. H. Initial evaluation, long-term monitoring, and hepatocellular carcinoma surveillance of chronic hepatitis B in routine practice: a nationwide US study. Am. J. Gastroenterol. 116, 1885–1895 (2021).
  PubMed Google Scholar
• Lazarus, J. V. et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat. Rev. Gastroenterol. Hepatol. 19, 60–78 (2021).
  PubMed Google Scholar